NF110

Cat. No.:	HY-108671
CAS No.:	111150-22-2
Molecular Formula:	$C_{41}H_{28}N_6Na_4O_{17}S_4$
Molecular Weight:	1096.91
Target:	P2X Receptor
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	NF110 is a $P2X_3$ receptor antagonist (K_i = 36 nM) and inactive toward P2Y receptors stably expressed (IC_{50}s > 10 M). NF110 blocks alphabeta-methylene-ATP-induced currents (IC_{50} = 527 nM) in rat dorsal root ganglia neurons[1].
IC_{50} & Target	Ki: 36 nM (P2X3 Receptor)
In Vitro	NF110 shows an activity in the human tumour cell line panel, with IC_{30} of 362.3 μM[2]. NF110 inhibits HMGA2-DNA interactions with an IC_{50} of 0.87 μM[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	NF110 shows potency at Endogenous P2X Receptors in Rat DRG Neurons, with a peak amplitude of 675 pA[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Hausmann R, et al. The suramin analog 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups. Mol Pharmacol. 2006;69(6):2058-2067.

[2]. Dhar S, et al. Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients. Eur J Cancer. 2000;36(6):803-809.

[3]. Su L, et al. Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays. Sci Rep. 2020;10(1):18850. Published 2020 Nov 2.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA